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Background: To test the efficacy of the recombinant tissue-type plasminogen activator (rt-PA) alteplase in horses,
the thrombolytic effect was tested in in vitro generated equine thrombi. The extent of lysis was determined by
measuring the decrease in thrombi weight over a period of 4 hours. In vivo pharmacokinetics of alteplase were
determined in 6 healthy horses. A single dose (1 mg/kg) was applied via intravenous infusion over a period of
30 minutes Coagulation-related variables, blood count and clinical parameters were taken before the treatment and
until 48 h after treatment. In addition, plasma rt-PA concentration was measured until 300 min after commencing
the infusion.
Results: In vitro, a dose dependent decrease of thrombus weight ranging from a 56 (± 6.5) % decrease for
0.5 μg/ml to 92 (± 2.1) % decrease for 5 μg/ml rt-PA was noted. The D-dimer concentration in the lysis medium
correspondingly increased from 0.10 up to 10.8 mg/l.
In vivo, none of the horses showed an adverse reaction to the alteplase infusion. In some horses blood parameters
were slightly altered. The 1 mg/kg dose yielded the following pharmacokinetic parameters: Cmax = 1.25 ± 0.27 μg/ml;
CL = 21.46 ± 5.67 ml/min/kg; dominant half life (t1/2α) = 6.81 ± 1.48 minutes; median elimination half life
(t1/2β) = 171 min (range: 85–1061); AUC = 50.33 ± 17.62 μg · min /ml.
Conclusion: These findings indicate that a single dose of 1 mg/kg alteplase results in rt-PA plasma concentrations
comparable to those in humans and might be sufficient for a thrombolytic therapy in horses. Further studies must
be performed to determine the alteplase effectiveness in horses with jugular vein thrombosis.
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Severe systemic diseases such as infections, inflammatory
disorders, septicemia, endotoxemia, and colic can be asso-
ciated with an activated coagulation state and predispose
horses to develop thrombophlebitis or thrombosis. Risk of
clot formation at the site of venepuncture is enhanced by
frequent venepuncture of the jugular vein, or the adminis-
tration of irritant pharmaceuticals, or by insertion of cath-
eter systems [1,2]. Treatment of thrombosis is directed
against further thrombus formation and commonly
performed with unfractioned heparin [3] or low-molecular
weight heparin [4]. Although recombinant hirudin, a* Correspondence: Karsten.Feige@tiho-hannover.de
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reproduction in any medium, provided the orspecific thrombin inhibitor that dissolves thrombi, has
been investigated experimentally [5], thrombolytic agents
are not commonly employed in equine medicine.
Tissue-type plasminogen activator (t-PA) is an endogen-
ous enzyme that induces lysis of intravascular thrombi by
the activation of plasminogen to plasmin, which degrades
the fibrin components of blood clots [6]. Alteplase is a re-
combinant human tissue-type plasminogen activator. It is
frequently used as a thrombolytic agent in human patients
with cardiac infarction or stroke [7,8]. In veterinary medi-
cine, experience with rt-PA is limited [9] and derive
mainly from experiences with cats suffering from aortic
thromboembolism and case reports in dogs [9,10]. There
are also few case reports for the use of rt-PA in horses. In
one case report a foal with aorto-iliac thrombosis received
a 2 mg dose of rt-PA intravenously [11]. Recombinantl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in a horse [12]. An intrapleural instillation of alteplase and
the newer generation plasminogen activator tenectoplase
was used in a fibrinolytic treatment of septic pleuropneu-
monia [13,14]. Recently, enecteplase was also used locally
to treat hyphema in a horse after ocular trauma [15].
However, to the author’s knowledge, pharmacokinetic data
of rt-PA in horses have not been reported yet.
Combined with commonly used anticoagulants, for
example heparin, rt-PA extends/augments thrombolytic
therapy options for humans and potentially for animals as
well [6,16]. Maximum plasma concentrations in humans
during the infusion (Cmax) of 0.5 mg/kg t-PA are in the
range of 900 to 1300 ng/ml [6,16]. These concentrations
were taken as approximate target values for the in vivo
study in horses. Thus, in the present study, the in vitro
capability of rt-PA on equine thrombi was tested and the
pharmacokinetics were evaluated in vivo in 6 adult horses.
Methods
In vitro study
Blood was collected from six mares and one gelding (all
Hannoverian horses) aged between 4 and 25 years. Horses
were owned by the Clinic for Horses, University of Veter-
inary Medicine, Hannover. All horses were clinically
healthy and haematological variables (WBC, RBC, haem-
atocrit, thrombocytes, fibrinogen, total plasma protein)
were within normal ranges. They had no systemic diseases
and were not involved in research projects 4 weeks prior
to the study. The horses were kept in individual box stalls,
fed hay and grain and were on pasture daily. The animal
experiment was approved by the German Government
(LAVES, no. 09/1796). Blood was obtained by venepunc-
ture of the jugular vein and collected into 50 ml vials
containing sodium citrate (1.3%) to prevent clotting. Sub-
sequently, blood was centrifuged (3000 g, 4°C, 10 min)
and plasma was stored at 4°C until used.
Siliconized glass vials (24 ml, Fa. Schott Fiolax, Mainz,
Germany) were filled with 4250 μl 0.9% NaCl, 200 μl
Ca-thromboplastin solution (Thromborel SW, Fa. Dade
Behring, Chicago, USA), and 500 μl CaCl2-solution (1.3%)
and incubated at 37°C for 20 min. Sodium citrate blood
(1000 μl) was added, and the vials were sealed with
parafilm (Parafilm MW, Firma Brand GmbH und Co AG,
Wertheim, Germany) and inverted several times. For co-
agulation the vials remained at 37°C for four hours. The
thrombi had a mean (± SD) weight of 2.92 ± 0.31 g. From
each horse 6 to 20 thrombi were generated. The thrombi
were transferred to Petri dishes (diameter 10 cm) and the
thrombi were fixed with a cotton wire.
Thrombolysis was performed in a water bath pre-
warmed to 37°C. Glass insets contained 20 ml autologous
horse plasma. Thrombi fixed with cotton fibres were
submerged in plasma. Plasma was continuously stirred bymeans of a magnetic stirrer (150 U/min). Effects of rt-PA
on equine thrombi were tested at concentrations of 0.5,
1.5, 3.5 and 5 μg/ml. Four horses were used for the
complete dose range (0 to 5 μg/ml rt-PA) and three add-
itional horses were taken for 0 and 1.5 μg/ml rt-PA. For
each concentration three to four thrombi obtained from
each horse were tested. For each time point and concentra-
tion the average of these three to four thrombi was taken.
Thrombolysis was determined by weight loss. Every
hour thrombi were transferred to a glass beaker filled
with 15 ml 0.9% NaCl and weighed. For the determin-
ation of the fibrin degradation product D-dimer, 200 μl
of the supernatant was collected every hour and stored
at −20°C until determination. D-dimer was detected with
a reflectometer (NycoCardW Reader II, Axis-Shield PoC
AS, Oslo, Norway) according to the manufacturer’s
protocol with in house- validation for horse samples.
In vivo study
Four mares and two geldings (three trotters, two
Hannoverian horses, one Swiss crossbred) were included in
the main in vivo study (no horses of the in vitro study were
used for the in vivo study). They were 5 to 17 years old and
weighed between 488 and 680 kg. The study was approved
by the German Government (LAVESno. 09/1796).
Two horses were used for dose finding studies and 6
horses were used for pharmacokinetic data analysis. The
general health status (heart frequency, respiratory rate,
evaluation of mucosa) was monitored frequently at the
beginning of rt-PA infusion and the frequency was re-
duced over the 24 h observation period.
The horses received catheter systems (EquiCath™
Fastflow; 12 G; 450 ml/min; B. Braun Vet Care GmbH,
Tuttlingen, Germany) in the right and left jugular veins.
One for administration of alteplase and one for blood
sampling. Before infusion of alteplase samples for
hematological examination were collected (t = 0) into dif-
ferent vacutainers (VacuetteW 4 ml, K3EDTA, Greiner
Bio- One GmbH, Frickenhausen, Germany). After collec-
tion, blood samples were centrifuged (10 min, 4°C,
3000 g) and plasma was stored at −80°C until analysis.
Additionally, coagulation status was checked every hour
after infusion started.
The rt-PA alteplase (ActilyseW, Boehringer-Ingelheim
Pharma GmbH und Co. KG, Ingelheim am Rhein,
Germany) was freshly prepared by dissolving the dry sub-
stance with the appropriate accompanying solvent to a
final concentration of 2 mg/ml. Alteplase was adminis-
tered intravenously over a 30 min period by means of an
infusion pump (InfusomatW fmS, B. Braun, Melsungen,
Germany). In a pilot study one horse received 0.25 mg/kg
and another received 0.5 mg/kg. In the main study, six
horses received 1 mg/kg alteplase. Blood samples were
taken directly before infusion (0), and 1, 6, 12, 18, 24, 30,
Figure 1 Reduction in thrombus weight of in vitro generated
equine thrombi after incubation with rt-PA (n = 4 horses for
concentrations 0.5, 3.0 and 5.0 μg/ml, n = 7 for 0 and 1.5 μg/ml
rt-PA; all thrombi for each time point and concentration were
performed a minimum of three times). After four hours, there is a
significant difference between 0 as well as 0.5 μg/ml and 1.5 μg/ml,
whereas no significant difference was found between 3 as well as
5 μg/ml and 1.5 μg/ml, a vs. b: p < 0.001.
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http://www.biomedcentral.com/1746-6148/9/15836, 48, 60, 72, 84, 96, 108, 120, 135, 150, 165, 180, 195,
210, 225, 240 and 300 min after infusion of alteplase. Sam-
ples were collected into a vacutainer (VacuetteW 9 ml 9NC
Coagulation sodium citrate 3.2%, Greiner Bio-One GmbH,
Frickenhausen, Germany). The first 10 ml of blood
obtained were discarded and the following 10 ml were col-
lected. The permanent-catheter systems were immediately
flushed with 10 ml 0.9% NaCl solution following insertion.
Analysis of hemostasis and rt-PA in plasma
Activated partial thromboplastin time (APTT-S TEClot-
Reagens, TECO Medical instruments Products and
Trading GmbH, Neufahrn, Germany and calcium-chloride-
solution (0,025 mol/l) Siemens Healthcare Diagnostics
Products GmbH, Marburg, Germany), the prothrombin time
(ThromborelW S, Siemens Healthcare diagnostics products
GmbH, Marburg, Germany), the thrombin time, TT
(Test Thrombin Reagens, Siemens Healthcare Diagnostics
Products GmbH, Germany) and fibrinogen (Multifibrin U
Siemens Healthcare Diagnostics Products GmbH, Germany)
were determined by means of a coagulometer (KC 1A,
Amelung, Lemgo, Germany).
Hematocrit, erythrocyte count, leukocyte count and
thrombocyte count were determined on an automated ana-
lyser (Sysmex KX-21 Deutschland GmbH, Norderstedt,
Germany). Agglutination of thrombocytes was excluded
microscopically. Total protein was analysed by means of a
refractometer (Euromex, Arnheim, Netherlands).
The determination of rt-PA was performed via enzyme
linked immunosorbant assay (ELISA) (AssayMax Human
Tissue-Type Plasminogen Activator ELISA Kit, Assay Pro,
St. Charles, MO, USA). The standard calibration was car-
ried out in horse plasma diluted 1:10 with dilution media,
as the instructions of the test kit required dilution of at least
1:10 to minimize plasma matrix interactions with the
ELISA. The calibration with rt-PA used for the study and
with the rt-PA provided with the kit were both highly linear
between 0.03 and 1 ng/ml, when plasma was diluted to at
least 1:10. Calibration curves with higher concentrations of
horse plasma led to non-linear curves. All samples were
thus diluted to at least 1:10 and plasma samples were di-
luted after pilot measurements to fit the linear area of 0.03
and 1 ng/ml. The intra-assay variance was 6.2%, inter-assay
variance, however, was up to 48.2%. Inter-assay variance
might be due to repeated freeze-thaw cycles of the samples
during the validation. It was therefore decided to aliquot
the samples of the main experiment to avoid repeated
freeze-thaw cycles. Additionally, crucial time points (around
Cmax) were measured on two different ELISAs and and the
mean of the two determinations was taken for analysis.
Statistical analysis
The results were analysed to determine whether there was
a significant difference between thrombus weights afterfour hours of incubation. Analysis was performed by one
way ANOVA followed by an adjusted Dunnett’s post hoc
test for unequal sample sizes. Changes in haematological
parameters over time were analysed by t-tests for multiple
comparisons using Bonferroni’s adjustment.
The pharmacokinetic parameters were calculated using a
two compartment model (WinNonlin 5.2, Pharssight Corp.,
Mountain View, CA, USA). The following pharmacokinetic
parameters were calculated: Plasma concentration at the
end of infusion (Cmax), area under the curve (AUC), total
plasma clearance (Cl) and plasma half lives (t1/2α, t1/2β).
Results
In vitro study
To determine the thrombolysis, the weight of the thrombi
and generation of D-dimer were measured every 60 min
over a period of four hours. There was a time dependent
decrease in thrombus weight and an increase in D-dimer
generation for equine thrombi (Figure 1, Table 1). An
addition of 1.5 μg/ml rt-PA to the autologous horse
plasma led to nearly 90% weight reduction of thrombi
4 hours after incubation, whereas 3.5 μg/ml and 5 μg/ml
increased this thrombolytic activity only marginally.
There was a time dependent increase of fibrin degrad-
ation product D-dimer by incubation with rt-PA, whereas
no such increase was observed with control thrombi
(no rt-PA added to horse plasma). The 0.5 and 1.5 μg/ml
concentration led to highest D-dimer formation, whereas
the effect was less pronounced at the higher concentra-
tions (3.5 and 5 μg/ml rt-PA, Table 1).
In vivo study
Infusion of rt-PA alteplase was well tolerated in the differ-
ent dosages by every horse. None of the horses showed
adverse drug reactions. In a pilot study, one horse received
Table 1 D-dimer formation during thromboylsis of in vitro generated equine thrombi (n = 4 horses for 0.5, 3.5 and
5 μg/ml rt-PA, n = 7 for 0 and 1.5 μg/ml rt-PA, all thrombi for each time point and concentration were performed at
least in triplicates)
t-PA (μg/ml) 0 h 1 h 2 h 3 h 4 h
0 0.10 (± 0.00) 0.10 (± 0.01) 0.10 (± 0.01) 0.11 (± 0.04) 0.11 (± 0.03)
0.5 0.12 (± 0.03) 1.83 (± 0.76) 4.40 (± 1.49) 7.72 (± 3.28) 10.08 (± 3.70)
1.5 0.11 (± 0.03) 4.74 (± 2.55) 8.08 (± 4.97) 9.25 (± 4.35) 9.78 (± 4.87)
3.5 0.12 (± 0.03) 1.87 (± 0.74) 2.70 (± 0.99) 4.14 (± 1.97) 4.64 (± 2.22)
5 0.12 (± 0.03) 1.77 (± 0.55) 2.98 (± 0.84) 4.22 (± 1.67) 5.32 (± 2.44)
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centration was 199 ng rt-PA/ml. By administration of
0.5 mg/kg rt-PA Cmax was 779 ng/ml. In order to achieve
plasma rt-PA concentrations consistent with those dem-
onstrated to be thrombolytic in vitro and in line with tar-
get concentrations in humans (Cmax around 1000 ng/ml) a
dose of 1 mg/kg was used for the main experiment. When
administered over 30 min via infusion, the mean maximal
plasma concentration measured was 1252 (± 267) ng/ml
rt-PA (Figure 2). The plasma clearance was 21.46 (± 5.67)
ml/min/kg and t1/2α was 6.81 (± 1.48) min followed by a
delayed β phase (t1/2β 317.93 ± 373.77 min). The high
standard deviation is due to the extremely prolonged t1/2β
in one horse (1061 min). The median t1/2β was 171 minutes
with a range of 85–1061 min.
The AUC was quite high due to the prolonged t1/2β
(50.33 ± 17.62 μg•min/ml). Mean blood and coagulation
parameters were within the reference range (Table 2).
However, activated partial thromboplastin time at hour
4 observation time was significantly reduced compared
to the basal value.
Discussion
The aim of the present study was to characterize the hu-
man recombinant plasminogen activator alteplase (rt-PA)
for use as a possible thrombolytic agent in equine patientsFigure 2 Time curve of rt-PA plasma concentration (mean ± SD)
after intravenous infusion of 1 mg/kg rt-PA over a period of
30 min in six healthy horses.suffering from thrombosis. After determining the in vitro
thrombolytic activity in equine thrombi, pilot pharma-
cokinetic data were obtained in healthy horses. Present
data indicate a dose dependent decrease in thrombus
weight induced by rt-PA in in vitro generated equine
thrombi. Interestingly, addition of more than 1.5 μg/ml
did not result in a significant increase of thrombolytic
activity and thus might be taken as a breakpoint and
maximal plasma concentration to be achieved by infu-
sion. Additionally, higher concentrations may increase
the risk of hemorrhage without increasing the efficacy.
A meta-analysis reveals that treatment of humans suf-
fering from pulmonary thromboembolism with rt-PA is
associated with hemorrhage in 8.8% of cases [9].
When comparing the present results with those pub-
lished for human in vitro generated thrombi (although the
experimental setting differed slightly), there seems to be a
difference in thrombolytic activity between human and
equine thrombi. In human thrombi, as little as 150 ng/ml
was sufficient to reduce the human thrombus weight by
50% within four hours and a nearly complete lysis of the
thrombus was achieved by approximately 600 ng/ml [17].
This difference in efficacy might be due to a slight differ-
ence in homology between equine and human t-PA. Two
isoforms are described for the equine tissue type plasmino-
gen activator (NCBI protein: accession no. XP_001489324,
XP_001489348) and according to BLAST (http://blast.
ncbi.nlm.nih.gov/) the homology to the human alteplase is
approximately 85%. Thus, equine plasminogen is not the
perfect substrate for human rt-PA, which has already been
demonstrated in an in vitro enzyme activity study [18].
There is approximately a 95% homology for the catalytic
side of plasminogen between horse and man (NCBI pro-
tein: accession no. AAD25984 and P00747). However, the
catalytic activity is less pronounced for human rt-PA [18]
and for streptokinase [19]. It is thus speculated that there
might be differences in the tertiary structure between hu-
man and equine plasminogen [19].
The in vivo study complements the finding that rt-PA
might be suitable as a thrombolytic agent in horses, as
maximal blood concentrations similar to those required for
thrombolysis in humans are achieved reliably. By an ad-
ministration of 1 mg/kg alteplase over a period of 30 min,
Table 2 Effects of rt-PA on haemostasis and further blood parameters (reference values in parentheses) in 6 horses of

























0 18.67 (±1.97) 85.50 (±15.23) 55.67 (±7.94) 1.13 (±0.16) 120.50 (±44.60) 7.67 (±1.06) 7.31 (±0.99) 36.83 (±3.19)
1 18.17 (±1.47) 93.50 (±10.46) 51.67 (±5.96) 1.12 (±0.13) 132.50 (±37.18) 7.45 (±1.23) 7.64 (±0.48) 37.50 (±3.15)
2 17.17 (±1.33) 97.00 (±4.69) 47.50 (±8.04) 1.14 (±0.19) 126.00 (±37.46) 7.32 (±1.23) 7.59 (±0.51) 37.00 (±2.83)
3 18.17 (±1.72) 88.83 (±15.69) 48.83 (±5.74) 1.13 (±0.14) 128.50 (±34.05) 8.00 (±0.79) 8.04 (±0.85) 40.15 (±5.02)
4 17.67 (±1.37) 95.00 (±7.75) 45.17 (±6.40)* 1.13 (±0.17) 126.50 (±32.02) 7.75 (±1.07) 7.74 (±0.50) 38.63 (±2.94)
5 17.50 (±1.64) 90.33 (±14.72) 50.17 (±8.77) 1.09 (±0.13) 114.00 (±23.82) 7.95 (±1.38) 7.85 (±0.52) 39.17 (±3.54)
12 19.67 (±1.51) 89.00 (±13.77) 55.00 (±6.16) 1.08 (±0.11) 150.17 (±41.73) 7.67 (±1.50) 7.95 (±0.45) 39.30 (±2.07)
24 18.50 (±0.84) 89.33 (±16.54) 54.83 (±5.19) 1.10 (±0.16) 127.83 (±44.20) 8.02 (±1.19) 8.22 (±1.10) 41.33 (±4.46)
36 18.50 (±0.84) 87.17 (±20.77) 57.17 (±6.21) 1.15 (±0.14) 139.33 (±37.89) 7.73 (±1.57) 8.54 (±1.03) 41.33 (±3.44)
48 18.50 (±1.05) 85.17 (±20.22) 56.33 (±6.77) 1.13 (±0.12) 132.67 (±36.66) 7.62 (±1.06) 8.01 (±0.66) 38.73 (±3.44)
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reached. This infusion was well tolerated by the horses,
and adverse effects were not observed. Only minor changes
in blood parameters were noticed in some individuals. The
reduced activated partial thromboplastin time at hour 4
observation time might not be of clinical significance as
such changes are commonly observed in ill patients or
under medication.
This is in accordance with observations in humans. No
effects on fibrinogen levels, prothrombin time and throm-
bin clotting times were observed after infusion of up to
0.5 mg/kg within 30 min in healthy human subjects. An
infusion of 0.5 mg/kg resulted in comparable maximal
blood concentrations of rt-PA to 1 mg/kg administered to
horses in the present study [16]. The clearance rate is
similar to findings in other species such as the approxi-
mate 10 to 20 mg/ml/min reported in man [6], but the ap-
parent volume of distribution is higher compared to that
determined in man [6]. Results obtained in humans
showed that the distribution of rt-PA, a protein with a mo-
lecular mass of 65,000, is restricted to the intravascular
space and well perfused tissues. It is assumed that most rt-
PA is removed from the circulation by specific uptake and
degradation in the liver [16]. The higher volume of distri-
bution found in horses may be explained by the com-
paratively long terminal half life. Nevertheless, the
concentrations found between 90 min and 300 min are
unlikely to play a clinically relevant role.
There are established methods for therapy of thrombi in
horses. For example, the coagulation inhibiting potential
of heparin is due to accelerating the complex formation
between antithrombin and various activated coagulation
factors, among which factor Xa and thrombin are the
most pivotal ones leading to a prevention of further clot
formation [4,20]. In contrast, recombinant hirudin, a
direct thrombin inhibitor acts independently of anti-thrombin activity and also inhibits fibrin bound thrombin
[5]. The mechanism of action of plasminogen activator
alteplase is advantageous in that it activates the thrombus
associated plasminogen to plasmin leading to a direct in-
duction of the fibrinolytic system [9]. With these proper-
ties rt-PA is an agent that is suitable for an initial
thrombolytic therapy that is indicated in early phases of
thrombosis, and should be combined or followed by a
heparin therapy to be most effective [7,8]. Due to the ini-
tial thrombolytic effect it could be expected that a similar
therapeutic regimen in horses is superior to commonly
performed anticoagulative therapies.
Recombinant t-PA has been used in dogs and cats with
varying results. The dosing regimen differs from study to
study (reviewed in [9]). Cats received total doses of 1 to
10 mg/kg with variable success. In one case report, a dog
with acute distal aortic thrombosis received a bolus injec-
tion of 1 mg/kg rt-PA every 60 min 10 times in succession.
After six days the dog received another 1.1 mg/kg as bo-
luses given 60 min apart, followed by two 0.7 mg/kg bo-
luses the next day. This procedure led to significant
clinical improvement [9].
Results obtained by the in vitro thrombolysis indicate
a thrombus reduction by approximately 86% when
thrombi are incubated with 1.5 μg/ml rt-PA. Based on
the in vitro findings it seems that at least 1 mg/kg
alteplase should be administered to achieve maximal
concentrations that lead to optimal lysis of the thrombi.
Collectively the results provide a basis for future
therapeutic investigations of thrombotic diseases using
rt-PA. The most promising results are anticipated for
the treatment of acute jugular thrombi as rt-PA might
induce complete thrombolysis. For chronic thrombi (e.g.
in the hind limbs) the success might be more limited if
results from human patients can be transferred to the
horse [21]. In one case report a foal with aorto-iliac
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The foal developed a severe coagulopathy and was eutha-
nized [17]. However, considering the pharmacokinetic data
obtained in the present study, a 2 mg infusion of rt-PA
might be too little to show any efficacy.
Conclusion
From the in vitro and in vivo data it is suggested that
rt-PA applied via intravenous infusion over a period of
30 minutes at a dose of 1 mg/kg might be suitable for
the treatment of thrombotic diseases in horses. This
dose regimen was not associated with severe adverse
effects which would have led to limitations for the use of
rt-PA in thrombotic horses.
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